Memorial Sloan Kettering Cancer Center (MSKCC) is a free-standing institution dedicated to the control of cancer through in-patient and out-patient care, clinical and research training programs, and a broad spectrum of research activities. MSKCC's research programs are grouped into three categories: Basic Research (Cellular Structure, Cell Signaling and Regulation, Developmental Biology, Genomic Integrity, and Molecular Structure); Bridge Disciplines (Cancer Biology and Experimental Pathology, Experimental Therapeutics, Immunology and Transplantation, and Imaging and Radiation Science), and Patient-Oriented Research (Clinical Research and Prevention, Control, and Population Research). The programs are designed to optimize the use of a large patient population and an extensive, multi-disciplinary staff of clinical and laboratory-based investigators, and to encourage the application of discoveries in the basic sciences in a way that advances the prevention, detection, diagnosis, and treatment of many forms of cancer. Scientific work in the eleven research programs depends on services provided by 36 core facilities, 20 of which will receive funding from the Cancer Center Support Grant (CCSG). During the next five years, under recently recruited leadership, MSKCC will enlarge its clinical and research facilities and its research and training programs; therefore, an expanded budget is requested to establish the laboratories of new investigators in several fields of inquire and to develop additional core facilities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA008748-41S5
Application #
7286495
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1977-01-01
Project End
2007-12-31
Budget Start
2006-01-01
Budget End
2006-12-31
Support Year
41
Fiscal Year
2006
Total Cost
$225,637
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Pun, Shawn C; Landau, Heather J; Riedel, Elyn R et al. (2018) Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation. J Am Soc Echocardiogr 31:64-70
Ring, Brian Z; Murali, Rajmohan; Soslow, Robert A et al. (2018) Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study. Cancer Epidemiol Biomarkers Prev 27:680-688
Shukla, Sachet A; Bachireddy, Pavan; Schilling, Bastian et al. (2018) Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell 173:624-633.e8
Chaft, Jamie E; Dagogo-Jack, Ibiayi; Santini, Fernando C et al. (2018) Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer. Lung Cancer 122:67-71
Petrovic, Ivana D; Migliacci, Jocelyn; Ganly, Ian et al. (2018) Ameloblastomas of the mandible and maxilla. Ear Nose Throat J 97:E26-E32
Nashat, Melissa A; Ricart Arbona, Rodolfo J; Lepherd, Michelle L et al. (2018) Ivermectin-compounded Feed Compared with Topical Moxidectin-Imidacloprid for Eradication of Demodex musculi in Laboratory Mice. J Am Assoc Lab Anim Sci 57:483-497
Roxburgh, Campbell S; Fenig, Yaniv M; Cercek, Andrea et al. (2018) Outcomes of Low-Grade Appendiceal Mucinous Neoplasms with Remote Acellular Mucinous Peritoneal Deposits. Ann Surg Oncol :
Forde, Patrick M; Chaft, Jamie E; Smith, Kellie N et al. (2018) Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med 378:1976-1986
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Buckley, Benjamin J; Aboelela, Ashraf; Minaei, Elahe et al. (2018) 6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer. J Med Chem 61:8299-8320

Showing the most recent 10 out of 8799 publications